220 related articles for article (PubMed ID: 18701504)
1. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
Yan W; Liu G; Scoumanne A; Chen X
Cancer Res; 2008 Aug; 68(16):6789-96. PubMed ID: 18701504
[TBL] [Abstract][Full Text] [Related]
2. Characterization of functional domains necessary for mutant p53 gain of function.
Yan W; Chen X
J Biol Chem; 2010 May; 285(19):14229-38. PubMed ID: 20212049
[TBL] [Abstract][Full Text] [Related]
3. Identification of GRO1 as a critical determinant for mutant p53 gain of function.
Yan W; Chen X
J Biol Chem; 2009 May; 284(18):12178-87. PubMed ID: 19258312
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function.
Gurtner A; Starace G; Norelli G; Piaggio G; Sacchi A; Bossi G
J Biol Chem; 2010 May; 285(19):14160-9. PubMed ID: 20223820
[TBL] [Abstract][Full Text] [Related]
5. p53 regulates FAK expression in human tumor cells.
Golubovskaya VM; Finch R; Kweh F; Massoll NA; Campbell-Thompson M; Wallace MR; Cance WG
Mol Carcinog; 2008 May; 47(5):373-82. PubMed ID: 17999388
[TBL] [Abstract][Full Text] [Related]
6. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.
Xia W; Bai H; Deng Y; Yang Y
J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124
[TBL] [Abstract][Full Text] [Related]
7. Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development.
Li H; Ji M; Klarmann KD; Keller JR
Blood; 2010 Aug; 116(7):1060-9. PubMed ID: 20453161
[TBL] [Abstract][Full Text] [Related]
8. Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells.
Yan W; Chen X
Cancer Res; 2007 Oct; 67(19):9117-24. PubMed ID: 17909016
[TBL] [Abstract][Full Text] [Related]
9. Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index.
Wilson JW; Deed RW; Inoue T; Balzi M; Becciolini A; Faraoni P; Potten CS; Norton JD
Cancer Res; 2001 Dec; 61(24):8803-10. PubMed ID: 11751402
[TBL] [Abstract][Full Text] [Related]
10. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
Zhang M; Xu E; Zhang J; Chen X
Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
[TBL] [Abstract][Full Text] [Related]
11. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1.
Fontemaggi G; Dell'Orso S; Muti P; Blandino G; Strano S
Cell Cycle; 2010 Jun; 9(12):2464-6. PubMed ID: 20519942
[No Abstract] [Full Text] [Related]
12. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
13. Stathmin/oncoprotein 18, a microtubule regulatory protein, is required for survival of both normal and cancer cell lines lacking the tumor suppressor, p53.
Carney BK; Cassimeris L
Cancer Biol Ther; 2010 May; 9(9):699-709. PubMed ID: 20200495
[TBL] [Abstract][Full Text] [Related]
14. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
Roger L; Jullien L; Gire V; Roux P
J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
[TBL] [Abstract][Full Text] [Related]
15. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
16. An N
Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
[TBL] [Abstract][Full Text] [Related]
17. S100A4 interacts with mutant p53 and affects gastric cancer MKN1 cell autophagy and differentiation.
Shen W; Chen D; Liu S; Chen L; Yu A; Fu H; Sun X
Int J Oncol; 2015 Dec; 47(6):2123-30. PubMed ID: 26497012
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
[TBL] [Abstract][Full Text] [Related]
19. ID1-, ID2-, and ID3-regulated gene expression in E2A positive or negative prostate cancer cells.
Asirvatham AJ; Carey JP; Chaudhary J
Prostate; 2007 Sep; 67(13):1411-20. PubMed ID: 17639499
[TBL] [Abstract][Full Text] [Related]
20. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
